Astellas, Medivation Launch Phase III Prostate Cancer Trial

“Medivation Inc. and Astellas Pharma Inc. announced enrollment of the first patient in a global phase III clinical trial, known as PROSPER, which will evaluate the safety and efficacy of enzalutamide in patients with nonmetastatic (often referred to as M0) castration-resistant prostate cancer (CRPC). Currently no prescription medicine is specifically approved for the treatment of patients with nonmetastatic CRPC in the U.S.”